Status:
COMPLETED
Long Term Implications of Rare Brain Tumours'
Lead Sponsor:
Galina Velikova
Collaborating Sponsors:
European Organisation for Research and Treatment of Cancer - EORTC
The Leeds Teaching Hospitals NHS Trust
Conditions:
Quality of Life
Cognitive Impairment
Eligibility:
All Genders
18+ years
Brief Summary
Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 an...
Detailed Description
The WHO classification of primary brain tumours has recently been updated and now also takes molecular parameters into account to provide clinicians with more accurate information on the expected dise...
Eligibility Criteria
Inclusion
- Histologically confirmed oligodendroglioma WHO grade II or III with IDH mutation and 1p/19q co-deletion
- Diagnosis must have been ≥5 years ago
- Patient is ≥18 years of age
- Willing and able to provide written informed consent
Exclusion
- They are expected to be unable to complete consent procedures and/or study outcomes due to legal incompetence or insufficient mastery of the language of the country in which they live as determined by their treating physician.
- They do not provide written informed consent
Key Trial Info
Start Date :
May 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2023
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT04708548
Start Date
May 29 2020
End Date
February 28 2023
Last Update
May 15 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, North Hollan, Netherlands, 1105 AZ
2
Leeds Institute of Medical Research
Leeds, West Yorkshire, United Kingdom, LS9 7FT